Yet, another study of MEG3 in CML showed increased methylation in CML patients when compared to healthy controls and suggested the use of the histone deacetylase inhibitor Chidamide to mitigate epigenetic silencing of MEG3 and miR-147 [118]. This evidence concerns the gene MEG3 and chronic myelogenous leukemia, BCR-ABL1 positive.